Edition:
India

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

124.90EUR
3:33pm IST
Change (% chg)

€0.60 (+0.48%)
Prev Close
€124.30
Open
€124.25
Day's High
€125.70
Day's Low
€124.25
Volume
89,326
Avg. Vol
447,936
52-wk High
€131.55
52-wk Low
€76.22

Latest Key Developments (Source: Significant Developments)

Merck Licenses CRISPR Technology To Pancella And Takara Bio Usa
Monday, 12 Oct 2020 

Oct 12 (Reuters) - MERCK KGAA ::LICENSES CRISPR GENOME-EDITING TECHNOLOGY TO PANCELLA AND TAKARA BIO USA.LICENSES AIM TO ACCELERATE DRUG DISCOVERY RESEARCH LEADING TO DEVELOPMENT OF NEW THERAPIES.  Full Article

Merck KGaA Out-Licensing Agreement For Phase II-Ready Anti-ADAMTS5 Nanobody For Osteoarthritis
Tuesday, 6 Oct 2020 

Oct 6 (Reuters) - MERCK KGAA ::ANNOUNCES OUT-LICENSING AGREEMENT FOR PHASE II-READY ANTI-ADAMTS5 NANOBODY FOR OSTEOARTHRITIS.MERCK RECEIVES UPFRONT PAYMENT OF € 50 MILLION WITH THE POTENTIAL OF RECEIVING A FURTHER € 400 MILLION RELATED TO DELIVERING ON CERTAIN DEVELOPMENT AND COMMERCIAL MILESTONES.M6495 IS BEING DEVELOPED WITH AIM TO BE SELF-ADMINISTERED VIA SUBCUTANEOUS INJECTIONS TO MAINTAIN STRUCTURAL INTEGRITY OF KNEE JOINT AND REDUCE PAIN.  Full Article

Merck Announces EUR 59 Million Antibody-Drug Conjugate Manufacturing Expansion
Wednesday, 9 Sep 2020 

Sept 9 (Reuters) - MERCK KGAA ::ANNOUNCES EUR 59 MILLION ANTIBODY-DRUG CONJUGATE MANUFACTURING EXPANSION.APPROXIMATELY 50 FULL-TIME JOBS TO BE ADDED.COMPLETION IS EXPECTED BY MID-2022 AND SHOULD ADD APPROXIMATELY 50 FULL-TIME JOBS STARTING IN 2021.  Full Article

Merck KGaA Says Placed 1 Billion EUR Hybrid Bond
Wednesday, 2 Sep 2020 

Sept 2 (Reuters) - Merck KGaA ::MERCK KGAA SAYS PLACED 1 BILLION EUR HYBRID BOND.  Full Article

Merck Announces Opening M Lab Collaboration Center In Shanghai
Friday, 10 Jul 2020 

July 10 (Reuters) - Merck KGaA ::MERCK KGAA, DARMSTADT, GERMANY ANNOUNCES OPENING OF ITS LIFE SCIENCE BUSINESS' LARGEST M LAB™ COLLABORATION CENTER IN SHANGHAI.  Full Article

Merck KGaA: EMA Validates Application For Cancer Drug Bavencio
Monday, 22 Jun 2020 

June 22 (Reuters) - Merck KGaA ::MERCK KGAA - EUROPEAN MEDICINES AGENCY VALIDATES APPLICATION FOR BAVENCIO® (AVELUMAB) FOR FIRST-LINE MAINTENANCE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA.A SUPPLEMENTAL NEW DRUG APPLICATION HAS ALSO BEEN ACCEPTED BY JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE FOR BAVENCIO AS A FIRST-LINE MAINTENANCE THERAPY FOR LOCALLY ADVANCED OR METASTATIC UC.  Full Article

Shanghai Junshi Biosciences Signs Clinical Trial Collaboration & Supply Deal With Merck KGaA
Monday, 1 Jun 2020 

June 1 (Reuters) - Shanghai Junshi Biosciences Co Ltd <1877.HK>::SIGNED CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH MERCK KGAA.PARTIES TO JOINTLY EXPLORE EFFICACY AND SAFETY OF TORIPALIMAB INJECTION.PARTIES TO EXPLORE EFFICACY & SAFETY OF TORIPALIMAB INJECTION IN COMBINATION WITH CETUXIMAB INJECTION.  Full Article

Merck Successfully Divests Allergopharma
Tuesday, 31 Mar 2020 

March 31 (Reuters) - MERCK KGAA ::SUCCESSFULLY DIVESTS ALLERGOPHARMA.THE TWO PARTIES HAVE AGREED NOT TO DISCLOSE THE PURCHASE PRICE.TRANSFER OF THE ALLERGOPHARMA BUSINESS IN CHINA IS PLANNED FOR THE SECOND HALF OF 2020.ALLERGY BUSINESS OF MERCK IN EUROPE WAS TRANSFERRED TO DERMAPHARM ON MARCH 31.  Full Article

Anteo Diagnostics Signs HOA With Merck
Monday, 9 Mar 2020 

March 9 (Reuters) - Anteotech Ltd ::SIGNED A NON-BINDING HEADS OF AGREEMENT WITH MERCK TO CO-DEVELOP ANTEOBIND ACTIVATED EUROPIUM PARTICLES.  Full Article

Merck To Invest EUR 250 Million Over 2019-2022 In New Facility
Monday, 27 Jan 2020 

Jan 27 (Reuters) - MERCK KGAA ::TO INVEST EUR 250 MILLION OVER 2019-2022 PERIOD IN NEW FACILITY BRIDGING RESEARCH AND MANUFACTURING.CONSTRUCTION OF BUILDING IS EXPECTED TO BE COMPLETED IN 2021.BIOTECH DEVELOPMENT CENTER IS ANTICIPATED TO BE FULLY OPERATIONAL BY END OF 2022 FOLLOWING VALIDATION BY REGULATORY AUTHORITIES.  Full Article